PYRIDOXINE HYDROCHLORIDE- pyridoxine hydrochloride injection, solution 
Mylan Institutional LLC



Pyridoxine hydrochloride injection is a sterile solution of pyridoxine hydrochloride in Water for Injection. Each mL contains 100 mg pyridoxine hydrochloride. pH adjusted with sodium hydroxide if necessary (2.0 to 3.8).

Pyridoxine hydrochloride, USP is a colorless or white crystal or a white crystalline powder. One gram dissolves in 5 mL of water. It is stable in air and is slowly affected by sunlight.

The chemical name is 2-methyl-3-hydroxy-4,5-bis (hydroxymethyl) pyridine hydrochloride. The structural formula is:

Pyridoxine Hydrochloride Structural Formula

The molecular weight is 205.6 g/mol and the molecular formula is C8H12ClNO3.


Natural substances that have vitamin B6 activity are pyridoxine in plants and pyridoxal or pyridoxamine in animals. All three are converted to pyridoxal phosphate by the enzyme pyridoxal kinase. The physiologically active forms of vitamin B6 are pyridoxal phosphate (codecarboxylase) and pyridoxamine phosphate. Riboflavin is required for the conversion of pyridoxine phosphate to pyridoxal phosphate.

Vitamin B6 acts as a coenzyme in the metabolism of protein, carbohydrate, and fat. In protein metabolism, it participates in the decarboxylation of amino acids, conversion of tryptophan to niacin or to serotonin (5-hydroxtryptamine), deamination, and transamination and transulfuration of amino acids. In carbohydrate metabolism, it is responsible for the breakdown of glycogen to glucose-1-phosphate.

The total adult body pool consists of 16 mg to 25 mg of pyridoxine. Its half-life appears to be 15 to 20 days. Vitamin B6 is degraded to 4-pyridoxic acid in the liver. This metabolite is excreted in the urine.

The need for pyridoxine increases with the amount of protein in the diet. The tryptophan load test appears to uncover early vitamin B6 deficiency by detecting xanthinurea. The average adult minimum daily requirement is about 1.25 mg. The ‘‘Recommended Dietary Allowance’’ of the National Academy of Sciences is estimated to be as much as 2.2 mg for adults and 2.5 mg for pregnant and lactating women. The requirements are more in persons having certain genetic defects or those being treated with isonicotinic acid hydrazide (INHJ) or oral contraceptives.


Pyridoxine hydrochloride injection is effective for the treatment of pyridoxine deficiency as seen in the following:

Inadequate dietary intake.

Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.

Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia.

The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired.


A history of sensitivity to pyridoxine or to any of the ingredients in pyridoxine hydrochloride injection is a contraindication.


WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Contains no more than 1900 mcg/L of aluminum.



Single deficiency, as of pyridoxine alone, is rare. Multiple vitamin deficiency is to be expected in any inadequate diet. Patients treated with levodopa should avoid supplemental vitamins that contain more than 5 mg pyridoxine in the daily dose.

Women taking oral contraceptives may exhibit increased pyridoxine requirements.

Drug Interactions

Pyridoxine supplements should not be given to patients receiving levodopa, because the action of the latter drug is antagonized by pyridoxine. However, this vitamin may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa.


Teratogenic Effects. Pregnancy Category A

The requirement for pyridoxine appears to be increased during pregnancy. Pyridoxine is sometimes of value in the treatment of nausea and vomiting of pregnancy.

Nursing Mothers

The need for pyridoxine is increased during lactation. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when pyridoxine hydrochloride is administered to a nursing woman.

Usage in Children

Safety and effectiveness in children have not been established.


Paresthesia, somnolence, and low serum folic acid levels have been reported.


Symptoms of dependence have been noted in adults given only 200 mg daily, followed by withdrawal.


Pyridoxine given to animals in amounts of 3 to 4 g/kg of body weight produces convulsions and death. In man, a dose of 25 mg/kg of body weight is well tolerated.


Pyridoxine hydrochloride injection may be administered intramuscularly or intravenously. In cases of dietary deficiency, the dosage is 10 mg to 20 mg daily for 3 weeks. Follow-up treatment is recommended daily for several weeks with an oral therapeutic multivitamin preparation containing 2 mg to 5 mg pyridoxine. Poor dietary habits should be corrected, and an adequate, well balanced diet should be prescribed.

The vitamin B6 dependency syndrome may require a therapeutic dosage of as much as 600 mg a day and a daily intake of 30 mg for life.

In deficiencies due to INH, the dosage is 100 mg daily for 3 weeks followed by a 30 mg maintenance dose daily.

In poisoning caused by ingestion of more than 10 g of INH, an equal amount of pyridoxine should be given – 4 g intravenously followed by 1 g intramuscularly every 30 minutes.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.


Pyridoxine Hydrochloride Injection USP, 100 mg/mL, is supplied in the following:

NDC 67457-281-01
carton containing 25, 1 mL multi-dose vials, (100 mg/mL)

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]


Use only if solution is clear and seal intact.


Preservative Free.

Manufactured for:
Mylan Institutional LLC
Rockford, IL 61103 U.S.A.

Manufactured by:
Mylan Institutional
Galway, Ireland


Revised: 10/2017


NDC 67457-281-01

Pyridoxine Hydrochloride
Injection, USP
100 mg/mL

For Intramuscular or Intravenous Use

Rx only          25 x 1 mL Multi-Dose Vials

Preservative Free


Each mL contains: Pyridoxine hydrochloride, USP 100 mg; water for injection,
q.s. pH adjusted with sodium hydroxide if necessary.

Contains no more than 1900 mcg/L of aluminum.

Usual Dosage: See accompanying prescribing information.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]


Use only if solution is clear and seal intact.

Manufactured for:
Mylan Institutional LLC
Rockford, IL 61103 U.S.A.

Manufactured by:
Mylan Institutional
Galway, Ireland


Pyridoxine Hydrochloride Injection 100 mg/mL Carton Label
pyridoxine hydrochloride injection, solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:67457-281
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Inactive Ingredients
Ingredient NameStrength
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:67457-281-0125 in 1 CARTON09/01/201604/30/2018
1NDC:67457-281-001 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Labeler - Mylan Institutional LLC (790384502)

Revised: 10/2017
Mylan Institutional LLC